JP2019521087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521087A5 JP2019521087A5 JP2018559845A JP2018559845A JP2019521087A5 JP 2019521087 A5 JP2019521087 A5 JP 2019521087A5 JP 2018559845 A JP2018559845 A JP 2018559845A JP 2018559845 A JP2018559845 A JP 2018559845A JP 2019521087 A5 JP2019521087 A5 JP 2019521087A5
- Authority
- JP
- Japan
- Prior art keywords
- adc
- administered
- use according
- seq
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337796P | 2016-05-17 | 2016-05-17 | |
| US62/337,796 | 2016-05-17 | ||
| PCT/US2017/033176 WO2017201204A1 (en) | 2016-05-17 | 2017-05-17 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009320A Division JP6870161B1 (ja) | 2016-05-17 | 2021-01-25 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521087A JP2019521087A (ja) | 2019-07-25 |
| JP2019521087A5 true JP2019521087A5 (enExample) | 2021-03-04 |
Family
ID=59014737
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559845A Pending JP2019521087A (ja) | 2016-05-17 | 2017-05-17 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2021009320A Active JP6870161B1 (ja) | 2016-05-17 | 2021-01-25 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2021068144A Active JP7150087B2 (ja) | 2016-05-17 | 2021-04-14 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2022152185A Pending JP2022185003A (ja) | 2016-05-17 | 2022-09-26 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009320A Active JP6870161B1 (ja) | 2016-05-17 | 2021-01-25 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2021068144A Active JP7150087B2 (ja) | 2016-05-17 | 2021-04-14 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2022152185A Pending JP2022185003A (ja) | 2016-05-17 | 2022-09-26 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20170348429A1 (enExample) |
| EP (4) | EP3804765A1 (enExample) |
| JP (4) | JP2019521087A (enExample) |
| KR (3) | KR20230028574A (enExample) |
| CN (3) | CN114246953B (enExample) |
| AU (1) | AU2017268342B2 (enExample) |
| BR (1) | BR112018073574A2 (enExample) |
| CA (1) | CA3024386C (enExample) |
| CY (2) | CY1123256T1 (enExample) |
| DK (2) | DK3458102T3 (enExample) |
| ES (2) | ES2864150T3 (enExample) |
| HR (2) | HRP20201186T1 (enExample) |
| HU (2) | HUE053332T2 (enExample) |
| IL (3) | IL294146B2 (enExample) |
| LT (2) | LT3458102T (enExample) |
| MX (1) | MX2018014175A (enExample) |
| NZ (1) | NZ748314A (enExample) |
| PL (2) | PL3626273T3 (enExample) |
| PT (2) | PT3626273T (enExample) |
| RS (2) | RS60663B1 (enExample) |
| RU (1) | RU2740996C2 (enExample) |
| SG (2) | SG11201810034XA (enExample) |
| SI (2) | SI3626273T1 (enExample) |
| SM (2) | SMT202000467T1 (enExample) |
| WO (1) | WO2017201204A1 (enExample) |
| ZA (1) | ZA201808386B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| HRP20210922T1 (hr) * | 2016-11-23 | 2021-09-03 | Eli Lilly And Company | Konjugati protutijela protiv met s lijekom |
| CN110144325A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| IL277049B2 (en) | 2018-03-13 | 2024-02-01 | Zymeworks Bc Inc | Conjugates of biparatopic anti-HER2 antibody and drug and methods of use |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| EP3774923A4 (en) * | 2018-03-28 | 2021-12-29 | Mitsubishi Tanabe Pharma Corporation | Drug conjugates of cmet monoclonal binding agents, and uses thereof |
| CA3114474A1 (en) * | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102353568B1 (ko) | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| MX2022001286A (es) * | 2019-07-30 | 2022-07-19 | Mythic Therapeutics Inc | Construcciones de proteínas de unión a antígenos y usos de estas. |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| CN112604004B (zh) * | 2019-09-19 | 2022-05-10 | 中国医学科学院医药生物技术研究所 | 一类抗人egfr抗体药物偶联物及其制备方法与应用 |
| CN110893236A (zh) * | 2019-10-09 | 2020-03-20 | 中山大学 | 溶酶体靶向的抗体药物偶联物及其应用 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| EP4129335A4 (en) * | 2020-09-01 | 2024-04-24 | RemeGen Co., Ltd. | ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS |
| CN116615455A (zh) * | 2020-09-12 | 2023-08-18 | 免疫医疗有限公司 | 用于抗b7h4抗体-药物缀合物疗法的评分方法 |
| WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| CN114533891B (zh) * | 2020-11-24 | 2023-04-18 | 深圳先进技术研究院 | 一种靶向无痕释放药物缀合物及其制备方法与应用 |
| RS66266B1 (sr) | 2021-02-03 | 2024-12-31 | Mythic Therapeutics Inc | Anti-met antitela i njihova primena |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| BR112023020562A2 (pt) | 2021-04-06 | 2023-12-05 | Abbvie Biotherapeutics Inc | Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina |
| IL306129A (en) | 2021-04-07 | 2023-11-01 | Mythic Therapeutics Inc | Structures of antigen-binding proteins and antibodies and their uses |
| BR112023020801A2 (pt) | 2021-04-08 | 2023-12-12 | Byondis Bv | Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica |
| TW202547842A (zh) * | 2021-04-29 | 2025-12-16 | 愛爾蘭商艾伯維製造管理無限公司 | 抗c-Met抗體藥物結合物 |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| WO2023173109A1 (en) | 2022-03-11 | 2023-09-14 | Abbvie Biotherapeutics Inc. | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib |
| CA3264074A1 (en) * | 2022-09-28 | 2024-04-04 | Zymeworks Bc Inc. | C-MET TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
| WO2024081729A2 (en) | 2022-10-12 | 2024-04-18 | Mythic Therapeutics, Inc. | Lrrc-15-binding protein constructs and uses thereof |
| US20240197906A1 (en) | 2022-12-11 | 2024-06-20 | Mythic Therapeutics, Inc. | ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF |
| FI131754B1 (en) * | 2023-03-13 | 2025-11-11 | Glykos Finland Oy | Antibody-exatecan conjugates |
| EP4713360A1 (en) | 2023-05-19 | 2026-03-25 | Les Laboratoires Servier | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
| CN121487754A (zh) * | 2023-07-25 | 2026-02-06 | 江苏恒瑞医药股份有限公司 | 靶向c-Met的抗体-药物偶联物及其医药用途 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025084851A1 (ko) * | 2023-10-19 | 2025-04-24 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-c-met 항체-약물 접합체 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025166213A1 (en) * | 2024-02-01 | 2025-08-07 | Fulgent Pharma Llc | Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane |
| WO2025245128A1 (en) | 2024-05-20 | 2025-11-27 | Mythic Therapeutics, Inc. | Antibody drug conjugates and therapeutic uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| AU2003256038A1 (en) | 2002-08-30 | 2004-03-19 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| KR20130065723A (ko) * | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4942643B2 (ja) * | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| DK3248613T3 (da) | 2005-07-18 | 2022-03-14 | Seagen Inc | Beta-glucuronid-lægemiddel-linkerkonjugater |
| US8940784B2 (en) | 2006-02-02 | 2015-01-27 | Syntarga B.V. | Water-soluble CC-1065 analogs and their conjugates |
| PT2099823E (pt) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| US20140112911A9 (en) | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
| AU2010254013A1 (en) | 2009-05-28 | 2011-11-24 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| EP2287197A1 (en) | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| US9337942B2 (en) | 2009-12-07 | 2016-05-10 | Ntt Docomo, Inc. | Propagation path estimation method and program and apparatus using the same |
| US20130004616A1 (en) | 2010-03-10 | 2013-01-03 | Novartis Ag | Streptococcus thermophilus bacterium |
| EP2553019A1 (en) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| DE102010012915A1 (de) | 2010-03-26 | 2011-09-29 | Schaeffler Technologies Gmbh & Co. Kg | Vorrichtung und Verfahren zur Ermittlung eines Schädigungszustands eines Radlagers |
| EP2402370A1 (en) | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| MX393973B (es) * | 2011-05-08 | 2025-03-24 | Legochem Biosciences Inc | Conjugados de proteína-agente activo y método para su preparación. |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| KR101463098B1 (ko) * | 2011-11-28 | 2014-11-27 | 한국생명공학연구원 | ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도 |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| UY34542A (es) | 2011-12-23 | 2013-07-31 | Mersana Therapeutics Inc | ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. |
| AU2013222935B2 (en) * | 2012-02-24 | 2016-03-10 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2014008375A1 (en) | 2012-07-05 | 2014-01-09 | Mersana Therapeutics, Inc. | Terminally modified polymers and conjugates thereof |
| CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
| WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
| MX2015012549A (es) * | 2013-03-15 | 2016-06-21 | Abbvie Deutschland | Formulaciones de conjugado anticuerpo anti-egfr-farmaco. |
| KR102150616B1 (ko) * | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
| ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
| WO2016165580A1 (zh) * | 2015-04-17 | 2016-10-20 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| CN106188293A (zh) * | 2015-04-17 | 2016-12-07 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| SI3626273T1 (sl) * | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
-
2017
- 2017-05-17 SI SI201730649T patent/SI3626273T1/sl unknown
- 2017-05-17 EP EP20208371.3A patent/EP3804765A1/en not_active Withdrawn
- 2017-05-17 BR BR112018073574-4A patent/BR112018073574A2/pt unknown
- 2017-05-17 KR KR1020237005212A patent/KR20230028574A/ko not_active Withdrawn
- 2017-05-17 IL IL294146A patent/IL294146B2/en unknown
- 2017-05-17 SG SG11201810034XA patent/SG11201810034XA/en unknown
- 2017-05-17 AU AU2017268342A patent/AU2017268342B2/en active Active
- 2017-05-17 EP EP19197371.8A patent/EP3626273B1/en active Active
- 2017-05-17 RS RS20200927A patent/RS60663B1/sr unknown
- 2017-05-17 CN CN202111593727.1A patent/CN114246953B/zh active Active
- 2017-05-17 DK DK17728311.6T patent/DK3458102T3/da active
- 2017-05-17 LT LTEP17728311.6T patent/LT3458102T/lt unknown
- 2017-05-17 KR KR1020227033500A patent/KR102512597B1/ko active Active
- 2017-05-17 PT PT191973718T patent/PT3626273T/pt unknown
- 2017-05-17 DK DK19197371.8T patent/DK3626273T3/da active
- 2017-05-17 KR KR1020187036427A patent/KR102449294B1/ko active Active
- 2017-05-17 HU HUE19197371A patent/HUE053332T2/hu unknown
- 2017-05-17 NZ NZ748314A patent/NZ748314A/en unknown
- 2017-05-17 SM SM20200467T patent/SMT202000467T1/it unknown
- 2017-05-17 RU RU2018144315A patent/RU2740996C2/ru active
- 2017-05-17 SG SG10201914095SA patent/SG10201914095SA/en unknown
- 2017-05-17 LT LTEP19197371.8T patent/LT3626273T/lt unknown
- 2017-05-17 CA CA3024386A patent/CA3024386C/en active Active
- 2017-05-17 CN CN201780044009.4A patent/CN109562189B/zh active Active
- 2017-05-17 EP EP17728311.6A patent/EP3458102B1/en active Active
- 2017-05-17 EP EP23163423.9A patent/EP4233909A3/en active Pending
- 2017-05-17 ES ES19197371T patent/ES2864150T3/es active Active
- 2017-05-17 ES ES17728311T patent/ES2811351T3/es active Active
- 2017-05-17 MX MX2018014175A patent/MX2018014175A/es unknown
- 2017-05-17 PL PL19197371T patent/PL3626273T3/pl unknown
- 2017-05-17 WO PCT/US2017/033176 patent/WO2017201204A1/en not_active Ceased
- 2017-05-17 SI SI201730337T patent/SI3458102T1/sl unknown
- 2017-05-17 JP JP2018559845A patent/JP2019521087A/ja active Pending
- 2017-05-17 HU HUE17728311A patent/HUE050398T2/hu unknown
- 2017-05-17 PT PT177283116T patent/PT3458102T/pt unknown
- 2017-05-17 CN CN202111566314.4A patent/CN114177308B/zh active Active
- 2017-05-17 US US15/597,624 patent/US20170348429A1/en not_active Abandoned
- 2017-05-17 SM SM20210122T patent/SMT202100122T1/it unknown
- 2017-05-17 PL PL17728311T patent/PL3458102T3/pl unknown
- 2017-05-17 RS RS20210246A patent/RS61659B1/sr unknown
- 2017-05-17 HR HRP20201186TT patent/HRP20201186T1/hr unknown
- 2017-05-17 IL IL262869A patent/IL262869B/en unknown
-
2018
- 2018-03-02 US US15/910,788 patent/US10383948B2/en active Active
- 2018-12-12 ZA ZA2018/08386A patent/ZA201808386B/en unknown
-
2019
- 2019-05-28 US US16/424,324 patent/US10603389B2/en active Active
-
2020
- 2020-01-17 US US16/746,497 patent/US20200215200A1/en not_active Abandoned
- 2020-08-10 CY CY20201100742T patent/CY1123256T1/el unknown
-
2021
- 2021-01-25 JP JP2021009320A patent/JP6870161B1/ja active Active
- 2021-02-25 HR HRP20210326TT patent/HRP20210326T1/hr unknown
- 2021-03-01 CY CY20211100168T patent/CY1123858T1/el unknown
- 2021-04-14 JP JP2021068144A patent/JP7150087B2/ja active Active
-
2022
- 2022-09-26 JP JP2022152185A patent/JP2022185003A/ja active Pending
-
2023
- 2023-02-22 US US18/172,769 patent/US20230321271A1/en not_active Abandoned
- 2023-07-25 IL IL304717A patent/IL304717A/en unknown